News Sentiment

HROW sentiment intelligence

Harrow Health Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 42.48 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-0.6% over one week, +12.9% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

Harrow Inc (HROW) Shares Surge 3.9% -- What GF Score of 81 Tells Investors

Market Reaction

Balanced read

52/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -0.6% Price digesting
Trend fit Trend inactive 12.9% over four weeks
Fair value 43.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 28
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 8
Market source 8
TradingView 7
Business Wire 4
Simply Wall Street 2
Insider Monkey 2
TradingKey 2
GlobeNewswire 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 15
Deals and strategy 6
Analyst action 2
Balance sheet 1
Regulatory and legal 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
富途牛牛 Direct company coverage

Analysts Are Optimistic We'll See A Profit From Harrow, Inc. (NASDAQ:HROW)

Analysts are predicting that Harrow, Inc. (NASDAQ:HROW) will soon become profitable, with a significant increase in revenue expected over the next few years. The average analyst price target suggests a substantial upside for the stock. However, investors should consider the compa

Tone
Positive 72/100
Event
Earnings
Published
09 Jul 2026 12:11
Source
富途牛牛
TradingView Direct company coverage

Price to earnings forward of Harrow, Inc. – NASDAQ:HROW

This article provides financial information for Harrow, Inc. (NASDAQ: HROW) on TradingView, specifically focusing on its Price to Earnings Forward metric. It indicates that the market is closed, with no current trades. The content is primarily a navigation and site structure page

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 05:10
Source
TradingView
Sahm Direct company coverage

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

Harrow announces the commercial launch of BYOOVIZ® (ranibizumab-nuna) in the United States, an FDA-approved interchangeable biosimilar referencing LUCENTIS. This launch expands Harrow's retina portfolio and strengthens its position in the rapidly growing retinal biologics market.

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 03:40
Source
Sahm
Eyes On Eyecare Direct company coverage

Harrow relaunches biosimilar Byooviz in the US

Harrow Inc. has re-launched BYOOVIZ (ranibizumab-nuna) in the U.S. commercial market, stemming from a partnership with Samsung Bioepis Co., Ltd. BYOOVIZ is an intravitreally-administered injection for treating wet age-related macular degeneration, macular edema following retinal

Tone
Positive 66/100
Event
Deals and strategy
Published
02 Jul 2026 21:10
Source
Eyes On Eyecare
TradingView Direct company coverage

Price to book forward of Harrow, Inc. – NASDAQ:HROW

The article references the "Price to book forward" for Harrow, Inc. (NASDAQ: HROW) and appears to be a financial data page from TradingView. It provides basic stock information and navigation elements, but the substantive financial data itself is not displayed in this snippet. Th

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 14:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Harrow, Inc. – NASDAQ:HROW

This article provides the "Price to sales forward" metric for Harrow, Inc. (NASDAQ: HROW) as presented on TradingView. It indicates that the market was closed at the time of viewing, with no trades reported. The content also briefly lists various financial data sources and featur

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 14:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Harrow, Inc. – NASDAQ:HROW

This article displays the "Enterprise value to EBITDA forward" for Harrow, Inc. (NASDAQ:HROW) on TradingView. It shows that the value is not available ("No trades") and provides information about the data sources used on the platform. The main focus is presenting a specific finan

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 05:41
Source
TradingView
Business Wire Direct company coverage

Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow

Samsung Bioepis has relaunched BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar to LUCENTIS, in the United States through a new partnership with Harrow. This relaunch aims to enhance access to critical retinal disease treatments like those for Wet Age-Related Macular Degen

Tone
Neutral 50/100
Event
Deals and strategy
Published
02 Jul 2026 02:40
Source
Business Wire
TradingView Direct company coverage

Enterprise value to revenue forward of Harrow, Inc. – NASDAQ:HROW

The article provides financial information for Harrow, Inc. (NASDAQ: HROW), specifically its enterprise value to revenue forward. It appears to be a stub or a section from a larger financial data platform, showing the company's ticker, market, and a period-specific value with cha

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 00:47
Source
TradingView
Stock Titan Direct company coverage

Harrow brings an interchangeable eye-drug biosimilar to U.S. retina care

Harrow (Nasdaq: HROW) has launched BYOOVIZ (ranibizumab-nuna) in the U.S., an FDA-approved interchangeable biosimilar referencing LUCENTIS for various retinal conditions like Wet AMD. This launch, following an exclusive commercialization agreement with Samsung Bioepis, expands Ha

Tone
Positive 74/100
Event
Market update
Published
01 Jul 2026 14:39
Source
Stock Titan
Stock Titan Direct company coverage

A first FDA-approved eye biosimilar returns to U.S. sales

Samsung Bioepis has relaunched BYOOVIZ (ranibizumab-nuna) in the US in partnership with Harrow, making the FDA-approved ophthalmology biosimilar referencing LUCENTIS available again. BYOOVIZ was the first ophthalmology biosimilar approved by the FDA in 2021 and received interchan

Tone
Positive 75/100
Event
Deals and strategy
Published
01 Jul 2026 11:11
Source
Stock Titan
Simply Wall Street Direct company coverage

How Grow Funds’ Exit and Weaker Earnings Recast Harrow’s (HROW) Growth Narrative and Governance Choices

Harrow, Inc.'s recent annual meeting approved director nominees and executive compensation, but Grow Funds' exit and disappointing earnings have cast doubt on the company's growth narrative. Investors are now more closely scrutinizing Harrow's ability to execute on product launch

Tone
Negative 29/100
Event
Earnings
Published
25 Jun 2026 23:09
Source
Simply Wall Street
TradingView Direct company coverage

Harrow, Inc. Actuals & Estimates (NASDAQ:HROW)

This article provides an overview of Harrow, Inc. (HROW) stock, including its current price, market capitalization, historical performance, and financial estimates. It details analyst forecasts, past earnings reports, future earnings dates, and revenue figures, emphasizing that t

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 16:09
Source
TradingView
TradingView Direct company coverage

HROW Forecast — Price Target — Prediction for 2027

This article provides a forecast for Harrow, Inc. (HROW) stock, including its current price, historical highs and lows, and analyst predictions for 2027. It also details financial metrics such as market capitalization, recent earnings, revenue, EBITDA, and upcoming earnings repor

Tone
Positive 65/100
Event
Earnings
Published
25 Jun 2026 14:41
Source
TradingView
Stock Titan Direct company coverage

Harrow (HROW) director granted 5,248 restricted stock units as compensation

Harrow, Inc. director Lauren P. Silvernail was granted 5,248 restricted stock units (RSUs) as compensation for her services. These RSUs will vest in equal quarterly installments over one year, contingent on her continued service with the company. The shares underlying these RSUs

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 04:10
Source
Stock Titan
Insider Monkey Direct company coverage

GROW Small Cap Equity Fund Covered Its Position in Harrow (HROW) in Q1

The GROW Small Cap Equity Fund covered its position in Harrow, Inc. (HROW) during Q1 2026, citing a disconnect between high street earnings expectations and the company's underlying growth. While the fund acknowledged Harrow's long-term potential, its conviction shifted towards A

Tone
Negative 38/100
Event
Earnings
Published
23 Jun 2026 08:06
Source
Insider Monkey
Investing.com UK Direct company coverage

Form 4 Harrow Health Inc For: 22 June By Investing.com

This article announces a Form 4 filing for Harrow Health Inc., dated June 22. It briefly mentions the company's stock symbol, HROW, and its -1.07% performance, alongside other financial market data and news headlines.

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 00:40
Source
Investing.com UK
Stock Titan Direct company coverage

Harrow (HROW) director Adrienne Graves receives 5,248 RSUs as compensation grant

Harrow, Inc. (HROW) director Adrienne L. Graves has been granted 5,248 Restricted Stock Units (RSUs) as compensation for her services. These RSUs will vest in equal quarterly installments over one year, contingent on her continued service. The underlying shares will not be delive

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 23:40
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] HARROW, INC. Insider Trading Activity

HARROW, INC. director Perry J. Sternberg reported the acquisition of 5,248 restricted stock units (RSUs) as compensation. These RSUs vest in equal quarterly installments over one year and will only be delivered as common shares after his service with the company ends. This transa

Tone
Neutral 50/100
Event
Deals and strategy
Published
22 Jun 2026 23:40
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 8K Harrow Health Inc For: 22 June By Investing.com

This article reports on the filing of a Form 8K by Harrow Health Inc. for June 22nd. It provides the stock symbol HROW and mentions its current performance. The content is brief and serves primarily as an announcement of the filing.

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 22:11
Source
Investing.com Canada
Investing.com South Africa Direct company coverage

Harrow elects directors and approves executive compensation at annual meeting By Investing.com

Harrow, Inc. (NASDAQ: HROW) shareholders elected four directors to its board, approved executive compensation, and ratified Deloitte & Touche LLP as its accounting firm during the 2026 Annual Meeting of Stockholders. The company's shares have seen significant gains over the past

Tone
Positive 58/100
Event
Market update
Published
22 Jun 2026 22:11
Source
Investing.com South Africa
Investing.com Direct company coverage

Harrow elects directors and approves executive compensation at annual meeting

Harrow, Inc. (NASDAQ: HROW) held its 2026 Annual Meeting where shareholders elected four directors to the board, approved executive compensation on an advisory basis, and ratified Deloitte & Touche LLP as its independent accounting firm for 2026. The company has seen a 10% stock

Tone
Positive 60/100
Event
Market update
Published
22 Jun 2026 11:39
Source
Investing.com
Stock Titan Direct company coverage

Harrow (HROW) investors back all 2026 director, pay and auditor proposals

Harrow, Inc. shareholders approved all proposals at their 2026 annual meeting, including the election of four directors, advisory approval of executive officer compensation, and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the

Tone
Neutral 50/100
Event
Regulatory and legal
Published
22 Jun 2026 11:39
Source
Stock Titan
Simply Wall Street Direct company coverage

Spotlight On Harrow And 2 Other Growth Stocks With Strong Insider Backing

This article highlights Harrow (HROW), Alphatec Holdings (ATEC), and AvePoint (AVPT) as growth stocks with significant insider ownership, suggesting strong confidence from management. Harrow, an eyecare pharmaceutical company, expects substantial revenue growth and future profita

Tone
Positive 73/100
Event
Earnings
Published
18 Jun 2026 11:40
Source
Simply Wall Street
TradingKey Direct company coverage

Harrow Inc (HROW) Financial Health: Profitability & Balance Sheet Analysis

Harrow Inc (HROW) holds a stable financial status with a score of 7.49, ranking 117th in the Pharmaceuticals industry. While its operating efficiency is high, the company reported a year-over-year revenue decrease of 7.59% and a significant net profit decrease of 55.24% in its la

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 09:40
Source
TradingKey
TradingKey Direct company coverage

Harrow Inc (HROW) Institutional Confidence

This article analyzes Harrow Inc.'s (HROW) institutional confidence, noting its current shareholding score of 5.00, placing it 73rd out of 157 in the Pharmaceuticals industry. Institutional shareholding has increased to 66.17% quarter-over-quarter. Private Capital is the largest

Tone
Positive 75/100
Event
Market update
Published
17 Jun 2026 09:11
Source
TradingKey